US equities
|
INTC
$112.50
▲+0.00%
MU
$1,045.56
▲+0.00%
SNDK
$1,660.46
▲+0.00%
NVDA
$239.24
▲+0.00%
SPCX
$171.92
▲+0.00%
MRVL
$287.01
▲+0.00%
AMD
$649.42
▲+0.00%
MSTR
$164.55
▲+0.00%
INTC
$112.50
▲+0.00%
MU
$1,045.56
▲+0.00%
SNDK
$1,660.46
▲+0.00%
NVDA
$239.24
▲+0.00%
SPCX
$171.92
▲+0.00%
MRVL
$287.01
▲+0.00%
AMD
$649.42
▲+0.00%
MSTR
$164.55
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
(OP:
MDXXF
)
0.1700
UNCHANGED
Delayed Quote
Updated: 10:24 AM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MDXXF
< Previous
1
2
Next >
Two Top Biotechs Forge MDMA Supply Deals For Clinical Research
↗
March 26, 2024
Via
Benzinga
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
March 20, 2024
Novel MDMA-Like Drug Could Be Used for Numerous Neurological and Psychiatric Indications
From
PharmAla Biotech
Via
GlobeNewswire
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
March 18, 2024
PharmAla now first company to supply both MDMA and Psilocybin into the Australian Market
From
PharmAla Biotech
Via
GlobeNewswire
Truffles To Market: Red Light Holland Wants To Develop Psilocybin API At Scale
↗
March 11, 2024
Via
Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
↗
February 15, 2024
Via
Benzinga
< Previous
1
2
Next >
